home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

319 rows where filing_period = "third_quarter", filing_year = 2019 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 319 ✖

filing_year 1

  • 2019 · 319 ✖

filing_period 1

  • third_quarter · 319 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2337392 CONNECT 4 STRATEGIES, LLC c2027d6d-0799-411e-b9ff-477ebffbd1be Q3 CONNECT 4 STRATEGIES, LLC 401103720 OREXO US, INC. 2019 third_quarter PHA Medicare and Medicaid access Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-09-28T13:11:09.150000-04:00
2337395 CONNECT 4 STRATEGIES, LLC e7de7d5e-af0b-4c91-b6ab-d7432db74826 Q3 CONNECT 4 STRATEGIES, LLC 401103720 RECORDATI RARE DISEASES 2019 third_quarter PHA CMS Issues Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-09-28T14:44:13.140000-04:00
2337397 CONNECT 4 STRATEGIES, LLC 8ce5a9b4-fbd4-4d39-918a-b44b566a523f Q3 CONNECT 4 STRATEGIES, LLC 401103720 AKCEA THERAPEUTICS, INC. 2019 third_quarter PHA FDA drug approval issues Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2019-09-28T14:55:14.820000-04:00
2337398 CONNECT 4 STRATEGIES, LLC 2866cdd0-fdb5-48d5-ba29-1f13ac6fabf7 Q3 CONNECT 4 STRATEGIES, LLC 401103720 FERRING PHARMACEUTICALS, INC. 2019 third_quarter PHA Medicare issues Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-09-28T14:58:15.697000-04:00
2337709 MCDERMOTT WILL & SCHULTE LLP f47834aa-8f07-4b4f-91d0-f2cdb2640f71 Q3 MCDERMOTT WILL & SCHULTE LLP 24338 MAXOR NATIONAL PHARMACY SERVICES, LLC 2019 third_quarter PHA Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, S. 1895, S. 2543 and H.R. 3. HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2019-10-01T15:02:11.140000-04:00
2337916 AMERICAN COLLEGE OF CLINICAL PHARMACY 9297e66e-eb69-45df-a2c1-d3c66673a028 Q3 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2019 third_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2019-10-02T10:28:01.477000-04:00
2338085 JOHNSON MATTHEY INC. f63af658-a856-49af-874f-603dc8b08a07 Q3 JOHNSON MATTHEY INC. 401104441 JOHNSON MATTHEY INC. 2019 third_quarter PHA H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers. HOUSE OF REPRESENTATIVES,White House Office   30000 0 0 2019-10-02T18:35:40.497000-04:00
2338809 ACG ADVOCACY a510e01f-0686-4a64-a34d-b3ba410adba6 Q3 ACG ADVOCACY 2057 WALGREEN CO. 2019 third_quarter PHA Drug Pricing Policy Issues. Data privacy and DIR fee reform. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-10-05T15:52:10.117000-04:00
2338913 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2a79a300-6778-42df-b9f9-c484af3317b3 Q3 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2019 third_quarter PHA Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2019-10-07T11:12:59.730000-04:00
2339018 RUBICON ADVISORS, LLC 253f7c02-2c02-4748-bbdb-9e93210217cf Q3 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2019 third_quarter PHA Prescription Drug User Fee HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2019-10-07T14:14:53.783000-04:00
2339060 RUBICON ADVISORS, LLC 9c0cd06d-4a8d-4dee-a131-0ad15b643148 Q3 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2019 third_quarter PHA Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2019-10-07T15:08:26.850000-04:00
2339062 RUBICON ADVISORS, LLC e7dabcdb-d0c1-470e-a2e4-5943142c296c Q3 RUBICON ADVISORS, LLC 315091 CONSCIOUS DISCIPLINE 2019 third_quarter PHA Medicare HOUSE OF REPRESENTATIVES,SENATE 37500   0 0 2019-10-07T15:09:28.900000-04:00
2339215 REPUBLIC CONSULTING, LLC e6542e6e-362a-46df-892a-c6536d33ddaf Q3 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2019 third_quarter PHA Monitor Data and Science Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-10-08T10:44:17.160000-04:00
2339666 MS. TAMI WAHL 149c6930-5c71-429b-b9b0-804ceb09ee2e 3T MS. TAMI WAHL 401104405 PARRY, ROMANI, DECONCINI & SYMMS ON BEHALF OF US COMPOUNDING PHARMACY 2019 third_quarter PHA Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act 503B) is in alignment with the statutory language. Legislative efforts include working on FDA issued guidance documents. HOUSE OF REPRESENTATIVES,SENATE     0 1 2019-10-09T12:23:28.813000-04:00
2339671 MS. TAMI WAHL 8ac88a1b-97d6-4121-86e6-263dc484963f 3T MS. TAMI WAHL 401104405 PARRY, ROMANI, DECONCINI & SYMMS ON BEHALF OF OLYMPIA PHARMACY 2019 third_quarter PHA Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act 503B) is in alignment with the statutory language. Legislative efforts include working on FDA issued guidance documents. HOUSE OF REPRESENTATIVES,SENATE     0 1 2019-10-09T12:26:35.897000-04:00
2339674 MS. TAMI WAHL f36e0a3e-ee4e-4964-9264-28ead668442a 3T MS. TAMI WAHL 401104405 PARRY, ROMANI, DECONCINI & SYMMS ON BEHALF OF FAGRON 2019 third_quarter PHA Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act 503B) is in alignment with the statutory language. Legislative efforts include working on FDA issued guidance documents. HOUSE OF REPRESENTATIVES,SENATE     0 1 2019-10-09T12:29:36.960000-04:00
2339677 MS. TAMI WAHL 0522f5ae-233e-406e-86db-503d01b2e549 3T MS. TAMI WAHL 401104405 PARRY, ROMANI, DECONCINI & SYMMS ON BEHALF OF BELMAR SELECT OUTSOURCING 2019 third_quarter PHA Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act 503B) is in alignment with the statutory language. Legislative efforts include working on FDA issued guidance documents. HOUSE OF REPRESENTATIVES,SENATE     0 1 2019-10-09T12:31:38.167000-04:00
2340007 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 4df7fbe2-8d83-4d81-a7b4-4ba38aff6664 Q3 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2019 third_quarter PHA Drug pricing, PCORI re-authorization, 340B Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   37650 0 0 2019-10-10T16:04:42.957000-04:00
2340131 MS. TAMI WAHL a64ae7cb-33c7-4bf5-8f75-27a678561c5c 3T MS. TAMI WAHL 401104405 OSRX, INC. 2019 third_quarter PHA Worked to ensure appropriate implementation of federal regulations and standards by providing background on pharmacy compounding and updates on imminent concerns to include the Memorandum of Understanding (Food, Drug and Cosmetic Act 503A(b)(3)(B)(ii)) and standards under the FDCA 503A(b)(1). HOUSE OF REPRESENTATIVES,SENATE     0 1 2019-10-10T16:05:43.990000-04:00
2340440 ISEMAN & ASSOCIATES LLC 254f2e3d-9891-48ca-8ec0-1d2aac4cda7d Q3 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2019 third_quarter PHA Monitoring biotech legislation; prescription drug prices HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2019-10-11T09:52:58.283000-04:00
2340553 MANATT, PHELPS, AND PHILLIPS 55832956-2029-4555-af60-6765b09d2e5b Q3 MANATT, PHELPS, AND PHILLIPS 23645 NEKTAR THERAPEUTICS 2019 third_quarter PHA FDA oversight of certain pain reliever products Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-10-11T11:39:06.153000-04:00
2340557 CARD & ASSOCIATES, LLC 78a1d3af-a0ac-440a-be4f-2d5a3fe6a9f0 Q3 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2019 third_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing S 1895 Lower Healthcare Costs Act HR 2296 Fair Accountability and Innovative Research Drug Pricing Act HR 2376 Prescription Pricing for the People Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-10-11T11:41:09.670000-04:00
2340677 SENTRY INSURANCE COMPANY (FORMERLY SENTRY INSURANCE A MUTUAL COMPANY) b39e6d60-b32e-4bc0-a20e-7fa6a75f2c1e Q3 SENTRY INSURANCE COMPANY (FORMERLY SENTRY INSURANCE A MUTUAL COMPANY) 401104022 SENTRY INSURANCE COMPANY (FORMERLY SENTRY INSURANCE A MUTUAL COMPANY) 2019 third_quarter PHA Monitoring the folllowing bills H.R 3947, Competition Prescription Act of 2019, all provisions H.R. 2296 METRIC Act, all provisions HOUSE OF REPRESENTATIVES,SENATE   60000 0 0 2019-10-11T13:55:18.903000-04:00
2340746 MCDERMOTT+ LLC 54c6cef0-6f8b-4a7e-844a-c837c482fe14 Q3 MCDERMOTT+ LLC 401103287 CAMPAIGN FOR SUSTAINABLE DRUG PRICING 2019 third_quarter PHA Issues relating to prescription drug pricing S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 340 and H.R. 965 - CREATES Act S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R. 2113 - Prescription Drug STAR Act H.R. 985 - FAST Generics Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2543 - Prescription Drug Pricing Reduction Act of 2019 Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-10-11T14:31:55.327000-04:00
2340907 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) bc7dff3d-05db-41ed-a719-7f9784ac27a1 Q3 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2019 third_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. HOUSE OF REPRESENTATIVES 45000   0 0 2019-10-12T10:42:55.533000-04:00
2340936 RED+BLUE STRATEGIES 342d36e3-73ba-4521-b954-8b883435e4d5 Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2019 third_quarter PHA H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act. S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines. CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace. C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. Policies related to the reform of Medicare Part B and D specific to the price of prescription medications. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-10-13T09:10:22.420000-04:00
2340938 RED+BLUE STRATEGIES 40b518c7-428a-4ef2-a260-3966f9bc943c Q3 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2019 third_quarter PHA S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. H.R. 3443 - The OTC Monograph Safety Innovation and Reform Act of 2019 - Support for policies that enable OTC monograph reform. Issues related to the implementation on the SUPPORT Act (P.L. 115-271) regarding MAT treatment. Issues related to curbing antibiotic resistance. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-10-13T09:20:24.133000-04:00
2340992 RED+BLUE STRATEGIES 3f04257f-8c42-4ec7-b689-82dd60af0dac Q3 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2019 third_quarter PHA H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. Health & Human Services, Dept of (HHS),SENATE 60000   0 0 2019-10-13T20:34:53.067000-04:00
2341049 INDEPENDENT PHARMACY COOPERATIVE f50ea529-d2a0-4527-8379-e979365e1e95 Q3 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2019 third_quarter PHA Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale. Proposed Regulation CMS-4180-P Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses. IPC supports. Proposed Regulation - OIG-0936-P Fraud and Abuse Removal of Federal Social Security Act Safe Harbor Protections for Prescription Drug Manufacturer Rebates and Safe Harbor Protections for Prescription Drug Point-of-Sale Price Reductions-IPC supports if a reasonable timeline is given to implement. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2019-10-14T09:45:31.787000-04:00
2341161 ICE MILLER LLP eb15131d-40d9-438a-9927-f8ac1841e0c7 Q3 ICE MILLER LLP 67854 ELI LILLLY AND COMPANY 2019 third_quarter PHA Issues related to pharmaceutical research and manufacturing Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-10-14T11:00:15.743000-04:00
2341193 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 4d75b65f-b4e2-45fe-8aec-4768260ef9ef Q3 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 INOVIO PHARMACEUTICALS 2019 third_quarter PHA Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-10-14T11:12:30.147000-04:00
2341229 POLSINELLI PC 49c46be6-48a5-47d7-beaf-3e7ade1c352c Q3 POLSINELLI PC 314911 TEVA PHARMACEUTICALS USA, INC. 2019 third_quarter PHA S.2543, Prescription Drug Pricing Reduction Act S.1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act H.R.2296, METRIC Act Administration review of drug pricing policies HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-10-14T11:24:44.610000-04:00
2341929 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 821d9898-5c59-4cb9-8d07-d12d084307ca Q3 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 third_quarter PHA H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 HOUSE OF REPRESENTATIVES,SENATE   680000 0 0 2019-10-15T10:44:25.867000-04:00
2341979 WINNING STRATEGIES WASHINGTON 725b98c5-4b3a-4db0-bc21-48f771bf2ace Q3 WINNING STRATEGIES WASHINGTON 50796 KALEO 2019 third_quarter PHA Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-10-15T10:58:44.710000-04:00
2342329 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. b70514c2-8879-4d19-a572-aa8956474791 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 AMERICAN SOCIETY OF HEMATOLOGY 2019 third_quarter PHA HR 1409, Cancer Drug Coverage Parity Act Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 30000   0 0 2019-10-15T12:21:56.150000-04:00
2342341 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 9df4496c-906a-4702-9bf7-a962c48f47b1 Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL HEMOPHILIA FOUNDATION 2019 third_quarter PHA Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs. Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2019-10-15T12:23:58.997000-04:00
2342345 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. c17cdeb2-7fd6-4d1c-aca4-6846ca6a55fe Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 THE HEMOPHILIA ALLIANCE 2019 third_quarter PHA Issues related to the 340B drug discount program and drug pricing policies Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-10-15T12:26:00.450000-04:00
2342354 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 7b010b90-562f-4336-8358-6830712f09da Q3 CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 8511 NATIONAL ASSOCIATION OF EPILEPSY CENTERS 2019 third_quarter PHA Issues related to anti-epileptic drugs. Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 10000   0 0 2019-10-15T12:28:01.967000-04:00
2342477 TAUZIN STRATEGIC NETWORKS 858ef5cf-b058-47e7-818c-5b943a96f6c3 Q3 TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2019 third_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-10-15T13:25:38.160000-04:00
2342739 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 0e492cf6-1860-4980-b941-d3c514db1d97 Q3 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 30212 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2019 third_quarter PHA Drug pricing, Direct and Indirect remuneration fees, Medicare Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2019-10-15T14:52:04.970000-04:00
2342865 POLITICAL CAPITAL, LLC 0d8a0f1c-5374-4f2c-b853-f34213c4c2f4 Q3 POLITICAL CAPITAL, LLC 401104260 MEDISCA INC 2019 third_quarter PHA Guidance documents, compounding pharmacy, appropriations language. Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2019-10-15T15:12:33.910000-04:00
2342875 POLITICAL CAPITAL, LLC 86e5bcfd-b943-45da-9ccd-b8dd3cc567e0 Q3 POLITICAL CAPITAL, LLC 401104260 PINE PHARMACEUTICALS 2019 third_quarter PHA Guidance documents, compounding pharmacy, appropriations language. Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-10-15T15:15:37.647000-04:00
2342885 POLITICAL CAPITAL, LLC 8196cd44-39dc-4fa5-9d3f-aec9ac4369ec Q3 POLITICAL CAPITAL, LLC 401104260 STOKES PHARMACY 2019 third_quarter PHA Compounding Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-10-15T15:16:40.117000-04:00
2342894 POLITICAL CAPITAL, LLC 3fd880bb-6d90-40f5-98f4-bbd378c53178 Q3 POLITICAL CAPITAL, LLC 401104260 KRS GLOBAL BIOTECHNOLOGY INC 2019 third_quarter PHA Compounding Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-10-15T15:17:43.540000-04:00
2343072 BROYDRICK & ASSOCIATES ef085c5d-b8dc-4607-8eff-71036a596650 Q3 BROYDRICK & ASSOCIATES 7268 EXELA PHARMA SCIENCES 2019 third_quarter PHA Drug shortages and FDA approval. USTR acceptance. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-10-15T16:05:35.887000-04:00
2343110 BROYDRICK & ASSOCIATES 6dd0828c-c0ff-4c54-a286-2b1704a49b4a Q3 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2019 third_quarter PHA Funding new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-10-15T16:16:51.023000-04:00
2343130 HANCE SCARBOROUGH 35d698db-d122-4bc8-98ab-459cbbd0e08f Q3 HANCE SCARBOROUGH 17443 PHRMA 2019 third_quarter PHA Patent reform regarding pharmaceutical research & products. SB 1416 by Sen. Cornyn. SENATE 20000   0 0 2019-10-15T16:23:02.777000-04:00
2343189 HANCE SCARBOROUGH 0c6bfb22-0c84-4b9b-a2c3-b6d830d6ec36 Q3 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2019 third_quarter PHA Issues related to the regulation of pharmacy compounding. HR 1959 Preserving Patient Access to Compounded Medications Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-10-15T16:47:29.550000-04:00
2343370 MR. VINCENT A. PANVINI 521533e8-1831-4daa-8bdb-12ce66c0bb09 Q3 MR. VINCENT A. PANVINI 401008845 PHRMA 2019 third_quarter PHA Position on Price Controls; Intellectual Property Rights; Patent Protections, Importation of Illegal Biopharmaceutical Drugs. HOUSE OF REPRESENTATIVES,SENATE 6000   0 0 2019-10-15T21:46:41.603000-04:00
2343377 THE MATHIS HARPLE GROUP e463cc60-6119-4c3b-bfb7-a1c3e80e971f Q3 THE MATHIS HARPLE GROUP 322911 PILMA 2019 third_quarter PHA HR 3, Price Controls, Intellectual Property Rights HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-10-15T22:34:46.847000-04:00
2343380 THE MATHIS HARPLE GROUP 4e0e9359-3675-4925-a47d-9df4fa67d6d7 Q3 THE MATHIS HARPLE GROUP 322911 PHRMA 2019 third_quarter PHA Price Controls, Intellectual Property Rights, Patent Protections, HR3 HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-10-15T23:06:49.783000-04:00
2343428 MARSHALL & POPP, LLC 2c8df2c3-304b-4428-96ad-34481420fbdf Q3 MARSHALL & POPP, LLC 401105121 AMGEN USA INC. 2019 third_quarter PHA Issues related to prescription drug value. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. 340B issues. Patents and protection of intellectual property issues. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office 60000   0 0 2019-10-16T08:46:17.793000-04:00
2343436 MARSHALL & POPP, LLC 1f91227c-46fd-41cd-975e-3fe5d99820ba Q3 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2019 third_quarter PHA Issues related to prescription drug value. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office 60000   0 0 2019-10-16T08:56:20.820000-04:00
2343456 MARSHALL & POPP, LLC 1d4ddacd-fcf7-49dc-87aa-505688bcc78c Q3 MARSHALL & POPP, LLC 401105121 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2019 third_quarter PHA Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office 50000   0 0 2019-10-16T09:10:27.567000-04:00
2343466 MARSHALL & POPP, LLC 5c11de4f-4c88-4fe0-ac8e-c39e8d96389c Q3 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2019 third_quarter PHA Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office 40000   0 0 2019-10-16T09:19:31.713000-04:00
2343747 WAXMAN STRATEGIES 78516471-d19b-4f54-9922-1224a44a76bf Q3 WAXMAN STRATEGIES 401103693 340B HEALTH 2019 third_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-10-16T10:37:20.417000-04:00
2344284 VANTAGEKNIGHT LLC 35b2e889-7407-4bf6-bdc2-43b46b2475cd Q3 VANTAGEKNIGHT LLC 401104100 CVS HEALTH 2019 third_quarter PHA Healthcare policy and policy issues related to accessible affordable options for quality pharmaceutical products   50000   0 0 2019-10-16T13:44:21.740000-04:00
2344436 NVG, LLC f971c253-257f-4f37-97bc-d06a957a20de Q3 NVG, LLC 76833 MANATT, PHELPS AND PHILLIPS, LLP (ON BEHALF OF NEKTAR THERAPEUTICS) 2019 third_quarter PHA FDA oversight of certain pain reliever products. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-10-16T14:23:22.400000-04:00
2344851 BROWN & FORTUNATO, P.C. 7d8fe6df-d11f-41b6-a313-335786e4aa98 Q3 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2019 third_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program. Centers For Medicare and Medicaid Services (CMS) 20000   0 0 2019-10-16T15:55:02.777000-04:00
2345016 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION a2a5e2ac-5aff-4516-acf6-c79e5ec4f422 Q3 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2019 third_quarter PHA Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number). Mandatory recall authority of the FDA Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R.3164 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 S.930 - Allowing Greater Access to Safe and Effective Contraception Act S.1847/H.R. 3296 - Affordability is Access Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 Commerce, Dept of (DOC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   166000 0 0 2019-10-16T16:39:58.537000-04:00
2345134 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 18f9b8ad-22df-4c98-9353-1729429a793c Q3 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2019 third_quarter PHA H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019; H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019; H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019; Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   320000 0 0 2019-10-16T17:33:37.973000-04:00
2345253 MEHLMAN CONSULTING, INC. b71498e6-8425-4896-8bf5-7e204cfb3f85 Q3 MEHLMAN CONSULTING, INC. 284950 FOOD ALLERGY RESEARCH & EDUCATION (FARE) 2019 third_quarter PHA Labeling of allergens. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-10-16T18:31:13.883000-04:00
2345265 MEHLMAN CONSULTING, INC. babb21df-6f88-4f55-be33-558e47b34c50 Q3 MEHLMAN CONSULTING, INC. 284950 BLUE SHIELD OF CALIFORNIA 2019 third_quarter PHA Prescription drug pricing. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-10-16T18:37:19.060000-04:00
2345595 AMERICAN VETERINARY MEDICAL ASSOCIATION 23545098-0460-4219-bee0-16b20113f047 Q3 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2019 third_quarter PHA H.R. 1607/S. 1290 Fairness to Pet Owners Act Agriculture, Dept of (USDA),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE   200000 0 0 2019-10-17T09:27:45.363000-04:00
2345981 GOVERNMENT COUNSEL, LLC 772f34ae-78a3-4b0f-b1ba-f172fb180495 Q3 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2019 third_quarter PHA Issues related to ARCOS data and suspicious order record requirements and reporting; H.R.3878-Block, Report, And Suspend Suspicious Shipments Act of 2019; importation of prescription drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844); implementation of Public Law 113-54 (DSCSA). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2019-10-17T10:53:48.080000-04:00
2346025 CAPITOL STRATEGIES GROUP, LLC e8ace7e4-e3c3-42c5-bf7c-3390f1d89084 Q3 CAPITOL STRATEGIES GROUP, LLC 400462294 PHRMA (ON BEHALF OF WE WORK FOR HEALTH ) 2019 third_quarter PHA Medicare Part B Medicare Part D Price Indexing Importation HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-10-17T11:00:00.117000-04:00
2346324 THE ROTUNDA GROUP LLC 8c735f92-3d88-4bd8-823a-510c8dcdb9c4 Q3 THE ROTUNDA GROUP LLC 401104124 MAGNA PHARMACEUTICALS, INC. 2019 third_quarter PHA illegal drug control policy Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE 7500   0 0 2019-10-17T11:47:50.720000-04:00
2346329 LUNGREN LOPINA LLC 93177d34-7366-4f88-8671-01d649d8b56b Q3 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2019 third_quarter PHA Fair treatment for US pharmaceutical ingredients Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-10-17T11:47:52.267000-04:00
2346718 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 8c4a0f49-065c-48f6-a495-6106f5ca5661 Q3 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 323876 BLUE CROSS AND BLUE SHIELD OF KANSAS INC 2019 third_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Rx Rebates; Biosimilars H.R. 1781 -- 116th Congress (2019-2020) Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R. 938 -- 116th Congress (2019-2020) BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 -- 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R. 1503 -- 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R. 1499 -- 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R. 965 -- 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] HOUSE OF REPRESENTATIVES,SENATE   5000 0 0 2019-10-17T13:03:06.023000-04:00
2346745 UNIVERSITY OF IOWA f454332b-76f1-4a6a-93ab-ba00a31c481f Q3 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2019 third_quarter PHA N/A Commerce, Dept of (DOC),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE   50000 0 0 2019-10-17T13:12:16.480000-04:00
2347094 BLUE CROSS BLUE SHIELD OF MICHIGAN 68e10de1-681e-43b4-a43d-32ebe0808df4 Q3 BLUE CROSS BLUE SHIELD OF MICHIGAN 46676 BLUE CROSS BLUE SHIELD OF MICHIGAN 2019 third_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars; Drug approval; Drug patents H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 - 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] H.R.3 - 116th Congress (2019-2020) Lower Drug Costs Now Act of 2019 Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.275 - 116th Congress (2019-2020) Medicare Prescription Drug Price Negotiation Act of 2019 Sponsor: Rep. Welch, Peter [D-VT-At Large] H.R.448 - 116th Congress (2019-2020) Medicare Drug Price Negotiation Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] HOUSE OF REPRESENTATIVES,SENATE   97200 0 0 2019-10-17T14:11:12.277000-04:00
2347185 CAREFIRST BLUECROSS BLUESHIELD f7f346a7-b440-4cb7-9834-d37d2f95a86c Q3 CAREFIRST BLUECROSS BLUESHIELD 401104608 CAREFIRST BLUECROSS BLUESHIELD 2019 third_quarter PHA Opioids; CREATES Act; Drug Pricing; Rebates H.R. 1499 - Protecting Consumer Access to Generic Drug Act H.R. 965 - CREATES Act of 2019 HOUSE OF REPRESENTATIVES,SENATE   100000 0 0 2019-10-17T14:29:43.243000-04:00
2347309 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. ead407ec-a383-460c-8d9c-f3e6a5985ea2 Q3 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2019 third_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs; Rx Rebates; Direct to Consumer Rx Advertising; Biosimilars; Drug Approval; Drug Patents HR 3 (116th Congress), Lower Drug Costs Now Act of 2019, by Rep. Frank Pallone, Jr. (D-NJ). To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes. HR 275 (116th Congress), Medicare Prescription Drug Price Negotiation Act of 2019, by Rep. Peter Welch (D-VT). To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate covered part D drug prices on behalf of Medicare beneficiaries. HR 448 (116th Congress), Medicare Drug Price Negotiation Act, by Rep. Elijah Cummings (D-MD). To amend title XVIII of the Social Security Act to provide for the negotiation of lower covered part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare part D, and for other purposes. HR 938 (116th Congress), Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (the BLOCKING Act) of 2019, by Rep. Kurt Schrader (D-OR). To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes. HR 965 (116th Congress), CREATES Act of 2019, by Rep. David Cicilline (D-RI). To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products. HR 1046 (116th Congress), Medicare Negotiation and Competitive Licensing Act of 2019, by Rep. Lloyd D… Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office   260000 0 0 2019-10-17T14:42:19.507000-04:00
2347362 HOLLAND & KNIGHT LLP 5f88b167-bd2d-42fc-a740-75e305d1ef43 Q3 HOLLAND & KNIGHT LLP 18466 TEVA PHARMACEUTICALS USA, INC. 2019 third_quarter PHA Drug pricing; Intellectual property; S.1895, Lower Health Care Costs Act; S.1416, Affordable Prescriptions for Patients Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-10-17T14:51:43.733000-04:00
2347796 ASSOCIATION OF AMERICAN MEDICAL COLLEGES 9e6dc4a3-22f3-4ae2-9998-cf36a536818c Q3 ASSOCIATION OF AMERICAN MEDICAL COLLEGES 4493 ASSOCIATION OF AMERICAN MEDICAL COLLEGES 2019 third_quarter PHA H.R. 965/S.340, The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 H.R. 985, The Fair Access for Safe and Timely (FAST) Generics Act of 2019 H.R. 1520, The Purple Book Continuity Act of 2019 H.R. 1503, The Orange Book Transparency Act of 2019 S. 659: Biologic Patent Transparency Act S. 617: Second Look at Drug Patents Act of 2019 H.R. 3, Lower Drug Costs Now Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 US-Mexico-Canada Agreement Issue: Support policies to reduce prescription drug prices Agency for Healthcare Research & Quality (AHRQ),Bureau of Citizenship & Immigration Services (BCIS),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Education, Dept of,Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Natl Science Foundation (NSF),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Science & Technology Policy (OSTP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office   1127000 0 0 2019-10-17T15:39:24.307000-04:00
2347916 PUBLIC CITIZEN 13a3129a-804e-4ff7-8211-3a960271afd8 Q3 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2019 third_quarter PHA HR 1046, S 377-Medicare Negotiation and Competitive Licensing Act, S 1987-End Price Gouging for Medications act, HR 3199-TERM Act, S 1895-Lower Health Care Costs Act, S 1209-(REMEDY act), S 1416-Affordable Prescriptions for Patients Act, HR 2374, S 1224-Stop STALLING Act, HR 3379-PRICED Act, HR 2296, S 1391-(FAIR Drug Pricing Act), drug pricing, HR 2296-METRIC Act, S 2004-Emergency Access to Insulin Act, S 2387-We protect American Investments in Drugs Act (We PAID Act), S 2199-Insulin Price Reduction Act, S 977-Transparent Drug Prices Act, S 378-Stop Price Gouging Act, S 340-CREATES Act, HR 3- Patient Advocacy Transparency Act, HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR)   70000 0 0 2019-10-17T15:52:00.927000-04:00
2348003 NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS b8f82ead-334f-4c00-940b-3dfeefe97de4 Q3 NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS 26808 NATIONAL ASSOCIATION OF BENEFITS AND INSURANCE PROFESSIONALS 2019 third_quarter PHA HR 3: A bill to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes. S 2543: A bill to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes. HR 3276: A bill to amend title XIX of the Social Security Act to exclude authorized generic drugs from calculation of the average manufacturer price for purposes of the Medicaid drug rebate program, and for other purposes. HR 2113: A bill to a mend titles XI and XVIII of the Social Security Act to provide for drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, and for other purposes. S. 1895: A bill to lower health care costs by preventing surprise medical bills, reducing prescription drug prices, improving transparency in health care, investing in public health and improving health information exchange. H.R. 1384: This bill establishes a national health insurance program that is administered by the Department of Health and Human Services (HHS). S. 1129: This bill establishes a national health insurance program that is administered by the Department of Health and Human Services (HHS). S. 981: A bill to establish a public health plan. HR 938: A bill to amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes HR 1520: A bill to amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and … Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,Treasury, Dept of,White House Office   330000 0 0 2019-10-17T16:04:26.673000-04:00
2348128 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 2acac252-c0df-495a-93fd-73f03163e555 Q3 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2019 third_quarter PHA Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   330432 0 0 2019-10-17T16:27:10.550000-04:00
2348162 KOUNTOUPES DENHAM CARR & REID, LLC 2c2c452b-17f3-4689-94ec-1b5527adde6d Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) 2019 third_quarter PHA Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-10-17T16:32:20.010000-04:00
2348827 PARAGON BIOSCIENCES, LLC 9b59a851-4fbf-42a5-a017-7782a7894ea4 Q3 PARAGON BIOSCIENCES, LLC 401105338 PARAGON BIOSCIENCES, LLC 2019 third_quarter PHA Issues related to public and private investment in biosciences and R&D S. 1249, American Innovation Act H.R. 2401, American Cures Act HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2019-10-17T20:12:14.943000-04:00
2348951 FORGE FEDERAL AFFAIRS LLC bdad1fd6-14dc-472f-b536-abc9acf89ba7 Q3 FORGE FEDERAL AFFAIRS LLC 400865535 LILLY USA LLC 2019 third_quarter PHA Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019. HOUSE OF REPRESENTATIVES 20000   0 0 2019-10-17T22:53:12.433000-04:00
2349150 BLUE CROSS AND BLUE SHIELD ASSOCIATION 27d004e4-246a-4dcc-b6d8-9cbdcec32bc7 Q3 BLUE CROSS AND BLUE SHIELD ASSOCIATION 6358 BLUE CROSS AND BLUE SHIELD ASSOCIATION 2019 third_quarter PHA Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars; Drug approval; Drug patents H.R.1781 - 116th Congress (2019-2020) Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R.938 - 116th Congress (2019-2020) BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 - 116th Congress (2019-2020) Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 - 116th Congress (2019-2020) Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - 116th Congress (2019-2020) Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 - 116th Congress (2019-2020) CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] H.R.3 - 116th Congress (2019-2020) Lower Drug Costs Now Act of 2019 Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.275 - 116th Congress (2019-2020) Medicare Prescription Drug Price Negotiation Act of 2019 Sponsor: Rep. Welch, Peter [D-VT-At Large] H.R.448 - 116th Congress (2019-2020) Medicare Drug Price Negotiation Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] H.R.1046 - 116th Congress (2019-2020) Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35] Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office   1530000 0 0 2019-10-18T09:05:39.883000-04:00
2349242 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 1a182948-fc19-4896-ad7f-dfe2c180f746 Q3 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2019 third_quarter PHA HR 4392- To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. H.R. 3. Lower Prescription Drug Costs Now Act - legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE   6852 0 0 2019-10-18T09:25:12.823000-04:00
2349438 TRAVERE THERAPEUTICS fb7bb0da-df4b-45e6-974f-4fbadce52a04 Q3 TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2019 third_quarter PHA H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   180000 0 0 2019-10-18T09:48:17.140000-04:00
2349673 LINCOLN PARK GROUP L.L.C. e3bb5672-cd5c-4de5-a682-971cadefd70c Q3 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2019 third_quarter PHA Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2019-10-18T10:18:39.027000-04:00
2349704 VAN SCOYOC ASSOCIATES 023b9ca5-5f0b-4928-977c-60cc2448dde1 Q3 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2019 third_quarter PHA Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2019-10-18T10:20:46.467000-04:00
2349807 FARRAGUT PARTNERS LLP 51f0f6d8-de2d-4f05-8315-13ae7e871036 Q3 FARRAGUT PARTNERS LLP 401103938 COMMUNITY ONCOLOGY ALLIANCE 2019 third_quarter PHA Issues related to pharmacy benefit managers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-10-18T10:29:10.427000-04:00
2349836 MASSACHUSETTS MEDICAL SOCIETY 5265b21a-216c-4cab-8ae6-959dfce98db5 Q3 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2019 third_quarter PHA Prescription Drugs H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act H.R. 2700 - Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act S. 340, H.R. 965 - Creating and Restoring Equal Access to Equivalent Samples Act of 2019 CREATES Act of 2019" - promote competition in the market for drugs and biological products by facilitating the timely entry of entry of lower-cost generic and biosimilar versions of those drugs and biological products H.R. 3 - The Lower Drug Costs Now Act S. 99, H.R. 448 - Medicare Drug Price Negotiation Act H.R. 275 - Medicare Prescription Drug Price Negotiation Act of 2019 Average Wholesale Price of Pharmaceuticals in Ads - no specific bill H.R. 2113 Prescription Drug STAR Act - Transparency of pharmaceutical prices across all sectors Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2019-10-18T10:31:20.037000-04:00
2349974 MCDERMOTT+ LLC 05a9e20f-c44f-4232-b774-d176f5ccc062 Q3 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2019 third_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-10-18T10:42:08.687000-04:00
2350025 TARPLIN, DOWNS & YOUNG, LLC 52812dae-4f60-4408-aa2f-7ec4ecc84740 Q3 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2019 third_quarter PHA Importation of prescription drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844) Opioid Abuse - General issues related to opioid drug abuse (Implementation of Public Law 115-271) Implementation of Public Law 113-54 (DSCSA) Issues Related to ARCOS data and suspicious order record requirements & reporting Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2019-10-18T10:46:30.863000-04:00
2350133 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 021e5079-612e-48fd-bb08-0f1ea6df6f4b Q3 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2019 third_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Support for S. 340/H.R. 965, Creating and Restoring Equal Access to Equivalent Samples Act of 2019. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   350000 0 0 2019-10-18T10:53:08.447000-04:00
2350456 ELI LILLY AND COMPANY 85b80e6e-606a-4bd8-8b08-33d6bbd9c57d Q3 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2019 third_quarter PHA Hospital discounts; 340B program Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1370000 0 0 2019-10-18T11:17:18.093000-04:00
2350815 HIGHMARK, INC. 7458a6e8-bda7-4964-8dc5-d23f289163a7 Q3 HIGHMARK, INC. 18238 HIGHMARK INC 2019 third_quarter PHA (Epidemic, Deterrence); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs; Rx Rebates; Biosimilars; Drug approval; Drug patents H.R.1781 - Payment Commission Data Act of 2019 Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1] H.R.938 -BLOCKING Act of 2019 Sponsor: Rep. Schrader, Kurt [D-OR-5] H.R.1520 - Purple Book Continuity Act of 2019 Sponsor: Rep. Eshoo, Anna G. [D-CA-18] H.R.1503 Orange Book Transparency Act of 2019 Sponsor: Rep. Kelly, Robin L. [D-IL-2] H.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019 Sponsor: Rep. Rush, Bobby L. [D-IL-1] H.R.965 CREATES Act of 2019 Sponsor: Rep. Cicilline, David N. [D-RI-1] H.R.3 - Lower Drug Costs Now Act of 2019 Sponsor: Rep. Pallone, Frank, Jr. [D-NJ-6] H.R.275 - Medicare Prescription Drug Price Negotiation Act of 2019 Sponsor: Rep. Welch, Peter [D-VT-At Large] H.R.448 - Medicare Drug Price Negotiation Act Sponsor: Rep. Cummings, Elijah E. [D-MD-7] H.R.1046 - Medicare Negotiation and Competitive Licensing Act of 2019 Sponsor: Rep. Doggett, Lloyd [D-TX-35] HOUSE OF REPRESENTATIVES,SENATE   300000 0 0 2019-10-18T11:48:06.357000-04:00
2350959 UC HEALTH 96d83d09-ec97-4c91-abea-02f632ea7e24 Q3 UC HEALTH 401103195 UC HEALTH 2019 third_quarter PHA 340B, drug prices Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2019-10-18T12:02:04.227000-04:00
2350999 FTI GOVERNMENT AFFAIRS 6fcfd307-9a0d-4c9d-9ae4-d1d4f316f293 Q3 FTI GOVERNMENT AFFAIRS 401054971 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2019 third_quarter PHA Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-10-18T12:04:15.470000-04:00
2351100 KOUNTOUPES DENHAM CARR & REID, LLC 13ec6bbf-09e2-4b15-ad14-6b1515d1bfe2 Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2019 third_quarter PHA General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H.R.269 and H. R. 3443, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-10-18T12:09:34.350000-04:00
2351309 GREATER NEW YORK HOSPITAL ASSOCIATION eae21c0e-0b7b-4d5c-ae2c-bb8bdd3684b8 Q3 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2019 third_quarter PHA Discuss issues related to group purchasing organizations (GPOs) with Congressional staff and members. Discuss several pieces of legislation with Congressional staff including: the CREATES Act (H.R. 965/S. 340) (support), the Fast Access for Safe & Timely Generics Act (H.R. 985) (support), the Protecting Consumer Access to Generic Drugs Act (H.R. 1499) (support), the Fair and Immediate Release of Generic Drugs Act (H.R. 1506) (support), the Orange Book Transparency Act (H.R. 1503) (support), the Purple Book Continuity Act (H.R. 1520) (support), and the Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics Act (H.R. 938) (support). Discuss the METRIC Act (H.R. 2296) with Congressional staff. Discuss potential legislation to address drug shortages with Congressional staff. Discuss the Prescription Drug Pricing Reduction Act of 2019 (S. 2543) with Congressional staff and committee staff. Discuss Lower Drug Costs Now Act (H.R.3) with Congressional staff. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Emergency Management Agency (FEMA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),President of the U.S.,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   650000 0 0 2019-10-18T12:34:32.370000-04:00
2351441 KOUNTOUPES DENHAM CARR & REID, LLC 8108d9ae-8f16-41b0-bb84-d9e8dc75ff2e Q3 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2019 third_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. Issues related to S.1895, the Lower Health Care Costs Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2019-10-18T12:57:16.640000-04:00
2351870 BURRELL INTERNATIONAL GROUP LLC badd5570-c705-4e56-86b7-edfeae97ba4d Q3 BURRELL INTERNATIONAL GROUP LLC 401103483 ACER THERAPEUTICS 2019 third_quarter PHA No specific legislative vehicles. Issues are, generally, orphan drug legislation, rare disease legislation, drug pricing policy HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2019-10-18T13:50:35.470000-04:00
2352091 SAS INSTITUTE 4b98b138-dee7-4880-b7f3-015237c0a30b Q3 SAS INSTITUTE 53243 SAS INSTITUTE 2019 third_quarter PHA Issues relating to the role of data and analytics to provide better insight for Centers for Medicare and Medicaid Services work on reducing drug prices Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Interior, Dept of (DOI),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),Overseas Private Investment Corp (OPIC),SENATE,White House Office   530000 0 0 2019-10-18T14:20:38.217000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1985.866ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API